
Bexson Biomedical, a private company in the psychedelics space, has inked a new agreement with Stevanato Group, an Italian-based provider of drug delivery solutions.
Bexson is currently developing an improved version of ketamine called BB106, which allows for subcutaneous delivery of the drug. The company received a patent from the USPTO for this formulation in 2021.